KyungDong Pharm home
Over-the-Counter Medicines

GinkgoB Tab. 240mg

Product Category
Cardiovascular Medicines
Active Ingredients
Ginkgo leaf dried extract
Appearance
Green, oblong, film-coated tablets
Reimbursement Code
-
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet (730.0 milligrams)
- Active ingredient: Ginkgo biloba dried extract (EP) · · · · · · · 240mg
- Additives (tar colorant): Red No. 40, Blue No. 1, Yellow No. 203
- Additives (animal-derived ingredients): Lactose hydrate (cow milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry QX green (321A610008), corn starch, colloidal silicon oxide, croscarmellose sodium, talc, Opadry EZ Clear 253U190007

2. Effectiveness
Deterioration of mental function accompanied by symptoms such as poor concentration, memory loss, and dizziness (symptoms of arteriosclerosis)

3. Dosage and dosage
adult
As ginkgo leaf dried extract, take 240 mg once, 1 tablet once a day.
Can be taken regardless of meal.

4. Precautions for use
1. The following people should not take (use) this medicine:
1) Patients with hypersensitivity to dried ginkgo biloba extract or other ingredients of this drug
2) There is not enough research on the use of this drug in children and adolescents. Therefore, this drug should not be used in children and adolescents under 18 years of age.
3) Pregnant women
4) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Do not take (use) the following medicines while taking (using) this medicine.
1) When anticoagulants (e.g., phenprocoumon, warfarin, clopidogrel, acetylsalicylic acid, and other non-steroidal anti-inflammatory drugs) are administered together (taken together), it cannot be ruled out that their efficacy is enhanced.
2) Like other medicines, it cannot be ruled out that this medicine affects the metabolism of various other medicines through cytochrome P450, 3A4, 1A2, 2E1, and 2C9, and may change the efficacy and/or duration of effect. When this drug is coadministered (taken together) with calcium channel blockers such as nifedipine and diltiazem, there is a risk of higher activity levels of these substances by affecting bioavailability. When coadministered (taken together) with oral theophylline, there is a risk of lower activity levels due to effects on excretion. Therefore, careful monitoring and dosage adjustments are required.

3. The following people should consult a doctor, dentist, or pharmacist before taking (using) this medicine.
1) Patients who have a bleeding disorder or are taking medications that increase the risk of bleeding should seek medical advice.
2) Lactating women (whether or not it transfers to breast milk is unknown)
3) It cannot be ruled out that taking (using) this drug may promote additional seizures in patients with epilepsy.

4. In the following cases, immediately stop taking (using) this drug and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) Taking (using) this drug may increase the risk of bleeding, so for safety reasons, you should stop taking (using) this drug at least 36 hours before surgery.
2) The duration of use should depend on the severity of symptoms and should last at least 8 weeks. If symptoms do not improve (improve) after 3 months or if symptoms worsen, you should check with your doctor to see if you can continue taking the medication (use).
3) Adverse reactions
• Gastrointestinal disorders: Gastrointestinal symptoms such as nausea.
• Nervous system: Very rare headache, insomnia, anxiety, confusion.
• Skin: Very rarely, allergic reactions (e.g. skin erythema (red spots), swelling, itching). Allergic shock may occur.
Cases of bleeding have been reported with long-term use.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Dizziness
• Itching
5) There are reports of anaphylaxis or anaphylactic reactions. However, this does not mean that the causal relationship with the relevant ingredient has been proven.

5. Other precautions when taking (using) this medicine
This drug is not a treatment for high blood pressure, so it should not be administered to patients with high blood pressure who require special treatment.

6. Storage precautions
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause deterioration in the quality of the medicine, so put it in the original container and keep it tightly closed.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 500 tablets/bottle

7. Period of use
36 months from date of manufacture